表达HBHA和hIL-12融合蛋白的重组耻垢分枝杆菌对结核分枝杆菌感染小鼠的免疫治疗作用

评价表达HBHA和hIL12融合蛋白的重组耻垢分枝杆菌用于结核分枝杆菌感染小鼠的免疫治疗效果.结核分枝杆菌H37Rv感染小鼠4周后,用表达HBHA和hIL12融合蛋白的重组耻垢分枝杆菌免疫治疗,检测免疫小鼠肺部荷菌量和组织病理变化.重组耻垢分枝杆菌可有效控制感染小鼠肺部结核分枝杆菌的荷菌量,减轻病理损伤.但在降低肺部荷菌量方面不如化疗药物.表达HBHA和hIL12融合蛋白的重组耻垢分枝杆菌可有效控制结核分枝杆菌在小鼠体内的增殖,可能成为联合化疗药物控制结核病的有效候选疫苗.

Therapeutic efficacy of a recombinant Mycobacterium smegmatis expressing an HBHA and hIL12 fusion protein against Mycobacterium tuberculosis infection induced in mice

We tried to investigate whether the HBHA-hIL12-rMS constructed could be effective as treatment against established infection. Mice were infected with the H37Rv strain via the tail vein. Four weeks after infection, the mice were were treated with HBHA-hIL12-rMS. Determination of bacterial burden and histopathology were performed at 8 weeks post-infection. The HBHA-hIL12-rMS decreased lung bacterial load in lungs and reduced lung damage compared to the saline, although cannot achieve therapeutic drug levels. The HBHA-hIL12-rMS could be effective as treatment against established infection. It may be a useful vaccine candidate combined treatment with the therapeutic drugs.